Akebia appoints Philip Vickers to board, replacing retiring Steven Gilman

Akebia Therapeutics, Inc.

Steven Gilman resigned as Class I director effective April 1, 2026; retirement not due to any disagreement.
Philip Vickers elected Class I director effective April 1, 2026; term expires at 2027 annual meeting.
Vickers appointed to Compensation and R&D Committees; receives standard non-employee director compensation.
Vickers granted 214,400 options at $1.41/share on April 1, plus annual cash retainers of $50,000.
Vickers is CEO of Solu Therapeutics; over 30 years biopharma leadership including Shire and Pfizer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.